Efficacy of a Low-Cost, Heat-Stable Oral Rotavirus Vaccine in Niger

This article, published in the New England Journal of Medicine, reports the results of a Phase 3 trial to assess the efficacy and safety of a heat-stable, live, oral bovine rotavirus pentavalent vaccine (BRV-PV) against severe rotavirus gastroenteritis among healthy infants in Niger. Unlike currently licensed rotavirus vaccines, BRV-PV does not require refrigeration. The authors conducted this study as part of an effort to identify rotavirus vaccines that are effective in low-resource settings, particularly in areas with unreliable transportation or cold storage systems. The results demonstrated vaccine efficacy of 66.7 percent against severe rotavirus gastroenteritis when administered in three doses to healthy infants. The authors concluded that the vaccine is reasonably efficacious with respect to morbidity and mortality from rotavirus in resource-constrained settings. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)

Author: Isanaka S, Guindo O, Langendorf C, et al.

Published: 2017

» Visit web page (English)

(Located at

CitationIsanaka S, Guindo O, Langendorf C, et al. Efficacy of a Low-Cost, Heat-Stable Oral Rotavirus Vaccine in Niger. New England Journal of Medicine. 2017;376:1121–1130.

Resource types: Peer-reviewed journal

Diseases/vaccines: Rotavirus

Topics: Vaccine safety and performance, Disease/vaccine specific information

Regions: Africa